share_log

B of A Securities Maintains Buy on Lyell Immunopharma, Lowers Price Target to $6

B of A Securities Maintains Buy on Lyell Immunopharma, Lowers Price Target to $6

美国银行证券维持对Lyell免疫治疗的买入评级,将目标价下调至6美元。
Benzinga ·  06/28 01:28

B of A Securities analyst Geoff Meacham maintains Lyell Immunopharma (NASDAQ:LYEL) with a Buy and lowers the price target from $9 to $6.

B of A Securities分析师Geoff Meacham维持Lyell Immunopharma(纳斯达克:LYEL)的买入评级,并将目标价从9美元降至6美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发